title: Review of 11 national policies for rare diseases in the context of key patient needs.
abstract: Rare diseases collectively exert a global public health burden in the severity of their manifestations and the total number of people they afflict. For many patients, considerable barriers exist in terms of access to appropriate care, delayed diagnosis and limited or non-existing treatment options. Motivated by these challenges, the rare disease patient community has played a critical role, elevating the patient voice and mobilizing legislation to support the development of programs that address the needs of patients with rare diseases.The US Orphan Drug Act of 1983 served as a key milestone in this journey, providing a roadmap for other countries to introduce and implement similar orphan drug legislation; more recently, the European Union (EU) has gone further to encourage the widespread adoption and implementation of rare disease plans or strategies designed to more adequately address the comprehensive needs of patients with rare diseases. Despite these legislative efforts and the growing contributions of patient advocacy groups in moving forward implementation and adoption of rare disease programs, gaps still exist across the policy landscape for several countries. To gain deeper insights into the challenges and opportunities to address key needs of rare disease patients, it is critical to define the current status of rare disease legislation and policy across a geographically and economically diverse selection of countries. We analyzed the rare disease policy landscape across 11 countries: Germany, France, the United Kingdom, Canada, Bulgaria, Turkey, Argentina, Mexico, Brazil, China, and Taiwan. The status and implementation of policy was evaluated for each country in the context of key patient needs across 5 dimensions: improving coordination of care, diagnostic resources, access to treatments, patient awareness and support, and promoting innovative research. Our findings highlight the continuing role of the patient community in driving the establishment and adoption of legislation and programs to improve rare disease care. Further, we found that while national rare disease plans provide important guidance for improving care, implementation of plans is uneven across countries. More research is needed to demonstrate the effect of specific elements of rare disease plans on patient outcomes.
authors.affiliation: Pfizer Inc., 235 E 42nd St, New York, NY, 10017, USA. Safiyya.Dharssi@pfizer.com.
authors.forename: Safiyya
authors.identifier: 0000-0002-9280-174X
authors.initials: S
authors.lastname: Dharssi
authors.affiliation: Canadian Organization for Rare Disorders, 151 Bloor Street West, Suite 600, Toronto, ON, M5S 1S4, Canada.
authors.forename: Durhane
authors.initials: D
authors.lastname: Wong-Rieger
authors.affiliation: Pfizer Inc., 235 E 42nd St, New York, NY, 10017, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Harold
authors.affiliation: Genetic Alliance, 4301 Connecticut Ave., NW, Suite 404, Washington, DC, 20008-2369, USA.
authors.forename: Sharon
authors.initials: S
authors.lastname: Terry
mesh_terms: D006291:Health Policy; D007880:Legislation, Drug; D009965:Orphan Drug Production / Q000331:legislation & jurisprudence*; D035583:Rare Diseases / Q000188:drug therapy*; D014481:United States
keywords: Asia; Europe; Legislation; National rare disease plan; North America; Patient advocacy; Policy; South America